People with type 2 diabetes and kidney disease whose kidney function dropped more in the first 12 weeks on semaglutide had higher predicted rates of serious kidney events two years later, according to a new analysis of the FLOW trial presented at the American Society of Nephrology's Kidney Week 2026. The same pattern appeared in patients taking a placebo, MedCentral reported in its meeting roundup.
The researchers stressed that the link does not show semaglutide caused kidney injury. The average early drop was nearly identical in both groups, about 1 point on the standard kidney function scale.
